AVALO THERAPEUTICS, INC. Costs and Expenses
AVALO THERAPEUTICS, INC. (AVTX) reported Costs and Expenses of $31.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-06-30 was $31.52M, a 63.17% increase year-over-year.
- AVALO THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-03-31 was $20.90M, a 42.48% increase year-over-year.
- AVALO THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-12-31 was $19.80M, a 46.64% increase year-over-year.
- AVALO THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-09-30 was $19.20M, a 46.44% increase year-over-year.
- AVALO THERAPEUTICS, INC. costs and expenses for fiscal 2025 was $72.98M, a 5.85% increase from fiscal 2024.
- AVALO THERAPEUTICS, INC. costs and expenses for fiscal 2024 was $68.95M, a 135.54% increase from fiscal 2023.
- AVALO THERAPEUTICS, INC. costs and expenses for fiscal 2023 was $29.27M, a 47.24% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. costs and expenses for fiscal 2022 was $55.49M, a 36.60% decline from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $31.52M 10-Q · filed 2026-08-06 | $52.42M 10-Q · filed 2026-08-06 | $72.22M derived: sum of 3 quarters · filed 2026-08-06 | $91.42M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $20.90M 10-Q · filed 2026-05-13 | $40.70M derived: sum of 2 quarters · filed 2026-05-13 | $59.90M derived: sum of 3 quarters · filed 2026-05-13 | $79.22M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $19.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $39.00M derived: sum of 2 quarters · filed 2026-03-23 | $58.31M derived: sum of 3 quarters · filed 2026-08-06 | $72.98M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $19.20M 10-Q · filed 2025-11-06 | $38.51M derived: sum of 2 quarters · filed 2026-08-06 | $53.18M 10-Q · filed 2025-11-06 | $66.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $19.32M 10-Q · filed 2026-08-06 | $33.98M 10-Q · filed 2026-08-06 | $47.49M derived: sum of 3 quarters · filed 2026-08-06 | $60.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $14.67M 10-Q · filed 2026-05-13 | $28.17M derived: sum of 2 quarters · filed 2026-05-13 | $41.28M derived: sum of 3 quarters · filed 2026-05-13 | $50.86M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $13.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $26.61M derived: sum of 2 quarters · filed 2026-03-23 | $36.19M derived: sum of 3 quarters · filed 2026-03-23 | $68.95M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $13.11M 10-Q · filed 2025-11-06 | $22.68M derived: sum of 2 quarters · filed 2025-11-06 | $55.45M 10-Q · filed 2025-11-06 | $63.68M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $9.57M 10-Q · filed 2025-08-07 | $42.34M 10-Q · filed 2025-08-07 | $50.57M derived: sum of 3 quarters · filed 2025-08-07 | $54.56M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $32.77M 10-Q · filed 2025-05-12 | $41.00M derived: sum of 2 quarters · filed 2025-05-12 | $44.98M derived: sum of 3 quarters · filed 2025-05-12 | $52.77M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $8.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $12.21M derived: sum of 2 quarters · filed 2025-03-20 | $20.01M derived: sum of 3 quarters · filed 2025-03-20 | $29.27M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $3.99M 10-Q · filed 2024-11-07 | $11.78M derived: sum of 2 quarters · filed 2024-11-07 | $21.05M 10-Q · filed 2024-11-07 | $30.80M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $7.79M 10-Q · filed 2024-08-12 | $17.06M 10-Q · filed 2024-08-12 | $26.81M derived: sum of 3 quarters · filed 2024-08-12 | $37.66M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $9.27M 10-Q/A · filed 2024-07-11 | $19.02M derived: sum of 2 quarters · filed 2024-07-11 | $29.87M derived: sum of 3 quarters · filed 2024-07-11 | $42.73M derived: sum of 4 quarters · filed 2024-07-11 | ||||
| 2022-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $20.61M derived: sum of 2 quarters · filed 2024-03-29 | $33.47M derived: sum of 3 quarters · filed 2024-03-29 | $55.49M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $10.85M 10-Q · filed 2023-11-09 | $23.71M derived: sum of 2 quarters · filed 2023-11-09 | $45.74M 10-Q · filed 2023-11-09 | $63.92M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $12.86M 10-Q · filed 2023-08-03 | $34.89M 10-Q · filed 2023-08-03 | $53.07M derived: sum of 3 quarters · filed 2023-08-03 | $70.88M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $22.03M 10-Q · filed 2023-05-04 | $40.21M derived: sum of 2 quarters · filed 2023-05-04 | $58.02M derived: sum of 3 quarters · filed 2023-05-04 | $78.50M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $18.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $35.99M derived: sum of 2 quarters · filed 2023-03-29 | $56.48M derived: sum of 3 quarters · filed 2023-03-29 | $87.53M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $17.81M 10-Q · filed 2022-11-07 | $38.30M derived: sum of 2 quarters · filed 2022-11-07 | $69.35M 10-Q · filed 2022-11-07 | $87.19M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $20.48M 10-Q · filed 2022-08-04 | $51.54M 10-Q · filed 2022-08-04 | $69.37M derived: sum of 3 quarters · filed 2022-08-04 | $83.76M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $31.05M 10-Q · filed 2022-05-05 | $48.89M derived: sum of 2 quarters · filed 2022-05-05 | $63.28M derived: sum of 3 quarters · filed 2022-05-05 | $76.43M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $17.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $32.22M derived: sum of 2 quarters · filed 2022-03-02 | $45.38M derived: sum of 3 quarters · filed 2022-03-02 | $79.54M 10-K · filed 2022-03-02 | $79.54M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $14.39M 10-Q · filed 2021-11-09 | $14.39M 10-Q · filed 2020-11-09 | $27.54M derived: sum of 2 quarters · filed 2021-11-09 | $61.71M 10-Q · filed 2021-11-09 | $61.71M 10-Q · filed 2020-11-09 | $68.01M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $13.15M 10-Q · filed 2021-08-02 | $13.15M 10-Q · filed 2020-08-06 | $47.32M 10-Q · filed 2021-08-02 | $47.32M 10-Q · filed 2020-08-06 | $53.62M derived: sum of 3 quarters · filed 2021-08-02 | $58.69M derived: sum of 4 quarters · filed 2021-08-02 | ||
| 2020-03-31 | $34.17M 10-Q · filed 2021-05-13 | $34.17M 10-Q · filed 2020-05-07 | $40.47M derived: sum of 2 quarters · filed 2021-05-13 | $45.53M derived: sum of 3 quarters · filed 2021-05-13 | $49.47M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $11.37M derived: sum of 2 quarters · filed 2021-03-08 | $15.31M derived: sum of 3 quarters · filed 2021-03-08 | $22.89M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $5.06M 10-Q · filed 2020-11-09 | $9.00M derived: sum of 2 quarters · filed 2020-11-09 | $16.58M 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | $3.94M 10-Q · filed 2020-08-06 | $11.52M 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $7.58M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $42.41M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |